AGC, a world-leading manufacturer of glass, chemicals and high-tech materials, has announced that it has entered into an agreement with Boehringer Ingelheim to acquire Malgrat Pharma Chemicals, S.L.U. (“MPC”). MPC is a subsidiary of Boehringer Ingelheim that manufactures synthetic pharmaceutical active ingredients¹ for the group. By acquiring MPC, AGC will have its first FDA registered site in Europe in the synthetic pharmaceutical CDMO² business.

MPC has vast experience manufacturing cGMP³-compliant commercialized synthetic pharmaceuticals as well as compounds in clinical development on a range of scales. Leveraging AGC’s fluorination technologies and extensive experience in in-house drug discovery and the CDMO business built up in Japan, AGC, with the addition of MPC, will be able to offer its CDMO services from a broader asset base, catering to European customer requirements and expanding its presence in the European market.

The AGC Group’s “AGC plus” management policy identifies life sciences as one of its strategic businesses. AGC will continue to actively invest in this field so as to be able to provide globally-unified high-quality services to customers in both the synthetic drug and biopharmaceutical businesses. Further, by maximizing the synergies of each location, the group’s technical capabilities will be enhanced, making it possible to better contribute to the pharmaceutical companies, patients, and wider society in general.

■About the AGC Group■
AGC Inc.(Headquarters: Tokyo, President & CEO: Takuya Shimamura) is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automotive and display glass, chemicals, ceramics and other high-tech materials and components. Based on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The AGC Group employs some 50,000 people worldwide and generates annual sales of approximately 1.5 trillion Japanese yen through business in about 30 countries. For more information, please visit www.agc.com/en

■About Boehringer Ingelheim■
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention. Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in the annual report: http://annualreport.boehringer-ingelheim.com.

■Profile of MPC■

Company	Malgrat Pharma Chemicals, S.L.U.
Established	2018
Location	Catalonia, Spain
Ownership ratio	Present Boehringer Ingelheim España, S.A. 100% After acquisition by AGC AGC 100%
Business description	Manufacture and sale of active pharmaceutical ingredients

■AGC Group sites engaged in life science business■